Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2017 (2017), Article ID 8758623, 7 pages
https://doi.org/10.1155/2017/8758623
Research Article

Correlation of Ezrin Expression Pattern and Clinical Outcomes in Ewing Sarcoma

1Department of Pediatrics, Emory University, Children’s Healthcare of Atlanta, Health Sciences Research Building, Brumley Bridge, 3rd Floor, W-350, 1760 Haygood Drive, Atlanta, GA 30322, USA
2Department of Pathology, Emory University, Children’s Healthcare of Atlanta, 1405 Clifton Road NE, Atlanta, GA 30322, USA
3Department of Pediatrics, Emory University, Children’s Healthcare of Atlanta, Health Sciences Research Building, Brumley Bridge, 4th Floor, W-440-B, 1760 Haygood Drive, Atlanta, GA 30322, USA
4Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA
5Department of Pediatrics, Emory University, Children’s Healthcare of Atlanta, 1405 Clifton Road NE, Atlanta, GA 30322, USA
6Department of Pediatrics, Vanderbilt University, Monroe Carell Jr. Children’s Hospital at Vanderbilt, 2220 Pierce Avenue, 396c Preston Research Building, Nashville, TN 37232, USA
7Department of Pediatrics, Emory University, Children’s Healthcare of Atlanta, Health Sciences Research Building, Brumley Bridge, 4th Floor, W-470, 1760 Haygood Drive, Atlanta, GA 30322, USA

Correspondence should be addressed to Thomas Cash

Received 23 September 2016; Revised 12 December 2016; Accepted 29 December 2016; Published 26 January 2017

Academic Editor: Dae-Geun Jeon

Copyright © 2017 Thomas Cash et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Ezrin is a membrane-cytoskeleton linker protein that has been associated with metastasis and poor outcomes in osteosarcoma and high-grade soft tissue sarcomas. The prognostic value of ezrin expression in Ewing sarcoma is unknown. Methods. The relationship between ezrin expression and outcome was analyzed in a cohort of 53 newly diagnosed Ewing sarcoma patients treated between 2000 and 2011. The intensity and proportion of cells with ezrin immunoreactivity were assessed in diagnostic tumor tissue using a semiquantitative scoring system to yield intensity and positivity scores for each tumor. Results. Ezrin expression was detected in 72% (38/53) of tumor samples. The proportion of patients with metastatic disease was equal in the positive and negative ezrin expression groups. There was no significant difference in the 5-year event-free survival (EFS) between patients with positive versus negative ezrin expression. Patients whose tumor sample showed high ezrin intensity had significantly better 5-year EFS when compared to patients with low/no ezrin intensity (78% versus 55%; ). Conclusions. Ezrin expression can be detected in the majority of Ewing sarcoma tumor samples. Intense ezrin expression may be correlated with a favorable outcome; however further investigation with a larger cohort is needed to validate this finding.